Mingus
Well-known member
http://fr.rian.ru/russia/20060620/49777268.html
Machine Translated
Russia
The first results of homologation of an anti-H5N1 vaccine for the man could be obtained this autumn
13:31
| 20 06/ 2006
SAINT-PETERSBOURG, June 20 - RIA Novosti. The Institute p?tersbourgeois of the influenza thinks of obtaining as of this autumn the first results of homologation of an anti-H5N1 vaccine for the man, Marianna Erofeeva announced, chief of laboratory in this establishment.
?So that the vaccine is definitively approved we should collect three samples of serum of blood of volunteers: before the inoculation of the vaccine and after the first and the second inoculation of the preparation ", Marianna Erofeeva indicated.
The Institute of the influenza hopes to obtain the three samples in August to then subject them to examinations at the public Institute of control in Moscow.
?The specialists in charge of this examination will not know the series to which the serum is referred nor when the samples were taken: before or after the inoculation of the preparation. In this way, by determining the quantity of antibody in the samples of blood they will be able to judge in all independence of the effectiveness of the vaccine ", the enquiring one raised.
The chief of laboratory also announced that 120 volunteers were implied in the tests of homologation of the anti-H5N1 vaccine.
?At certain people one observed the first days having followed the inoculation a certain push of temperature, reaching 37,4 maximum. This phenomenon is possible during the tests of homologation ", Marianna Erofeeva added by specifying that no complication had been done day up to now.
The anti-H5N1 vaccine for the man in the course of homologation was elaborate at the Institute p?tersbourgeois influenza starting from a stock of virus H5N1 according to the method of the opposite genetics.
There is some time the director of this establishment, Oleg Kissiliev, had announced with RIA Novosti that ?the preparation is a vaccine known as of reserve and that it would not constitute a panacea in the event of pandemia of avian flu?.
Machine Translated
Russia
The first results of homologation of an anti-H5N1 vaccine for the man could be obtained this autumn
13:31
| 20 06/ 2006
SAINT-PETERSBOURG, June 20 - RIA Novosti. The Institute p?tersbourgeois of the influenza thinks of obtaining as of this autumn the first results of homologation of an anti-H5N1 vaccine for the man, Marianna Erofeeva announced, chief of laboratory in this establishment.
?So that the vaccine is definitively approved we should collect three samples of serum of blood of volunteers: before the inoculation of the vaccine and after the first and the second inoculation of the preparation ", Marianna Erofeeva indicated.
The Institute of the influenza hopes to obtain the three samples in August to then subject them to examinations at the public Institute of control in Moscow.
?The specialists in charge of this examination will not know the series to which the serum is referred nor when the samples were taken: before or after the inoculation of the preparation. In this way, by determining the quantity of antibody in the samples of blood they will be able to judge in all independence of the effectiveness of the vaccine ", the enquiring one raised.
The chief of laboratory also announced that 120 volunteers were implied in the tests of homologation of the anti-H5N1 vaccine.
?At certain people one observed the first days having followed the inoculation a certain push of temperature, reaching 37,4 maximum. This phenomenon is possible during the tests of homologation ", Marianna Erofeeva added by specifying that no complication had been done day up to now.
The anti-H5N1 vaccine for the man in the course of homologation was elaborate at the Institute p?tersbourgeois influenza starting from a stock of virus H5N1 according to the method of the opposite genetics.
There is some time the director of this establishment, Oleg Kissiliev, had announced with RIA Novosti that ?the preparation is a vaccine known as of reserve and that it would not constitute a panacea in the event of pandemia of avian flu?.